Volume 16 Number 6 (March 15th, 2008) reporting from:
4th European Congress on Hematologic Malignancies (February 22-24, 2008, Paris)
American Society of Hematology Annual Meeting (December 8-11, 2007 Atlanta)
Chemotherapy Foundation Symposium, November 7-10, 2007, New York
David Maloney
Nonmyeloablative
…
Live Report from ASH:
Ibritumomab Provides Benefit in Patients with Follicular Lymphoma+
11th December 2007
Live Report from ASH: Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes+
10th December 2007
Pierre Fenaux
Results from a phase III study presented at ASH suggest that the hypomethylating agent azacitidine should be the new standard of care for patients with high-risk MDS. Pierre Fenaux of Paris 13 University
…
Large Risk Reduction For Rivaroxaban In Blood Clot Prevention+
9th December 2007
Bengt Eriksson
BENGT ERIKSSON, Gothenburg University
In a large phase III trial of patients having a hip replacement, the oral anticoagulant rivaroxaban has shown significant benefit when
…
Rituximab Maintenance after Chemotherapy Gives Better Outcomes in Advanced Follicular Lymphoma+
21st December 2005
Sandra Horning
Abstract 349
Sandra Horning, Stanford University Medical Center
It is not necessary to use rituximab along with standard CVP (cyclophosphamide, vincristine, predinsone) induction therapy in patients with advanced follicular lymphoma. However, the use of rituximab maintenance, after induction …
Targeted Therapies in Multiple Myeloma Treatment Decisions+
21st December 2005
Vincent Rajkumar
Vincent Rajkumar, Divison of Hematology, Mayo Clinic
At a section of the hematology meeting talking about newly diagnosed multiple myeloma and the evolving treatments, Vincent Rajkumar discussed new agents such as lenolidamide and thalidomide. Audio Medica asked him …
Pro-Apoptosis, mTOR Pathways: New Targets for Lymphoma+
21st December 2005
Owen O’Connor
Owen O’Connor, Memorial Sloan-Kettering Cancer Center, New York
Owen O’Connor also gave data from early, two studies: one looking at treating lymphoma with the drug SAHA which targets BCL-6 in the tumor preventing it’s anti-apoptotic influence; the other …